Evidence map›Paper›PMID 33315907›Full record

ArticlePloS one2020

5,5-Dialkylluciferins are thermal stable substrates for bioluminescence-based detection systems.

Ce Shi, Michael P Killoran, Mary P Hall, Paul Otto, Monika G Wood, Ethan Strauss, Lance P Encell, Thomas Machleidt, Keith V Wood, Thomas A Kirkland

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 53% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Ce ShiPromega Biosciences, Inc., San Luis Obispo, California, United States of America.
Michael P KilloranPromega Corporation, Madison, Wisconsin, United States of America.ORCID 0000-0002-0529-7590
Mary P HallPromega Corporation, Madison, Wisconsin, United States of America.
Paul OttoPromega Corporation, Madison, Wisconsin, United States of America.
Monika G WoodPromega Corporation, Madison, Wisconsin, United States of America.
Ethan StraussPromega Corporation, Madison, Wisconsin, United States of America.
Lance P EncellPromega Corporation, Madison, Wisconsin, United States of America.
Thomas MachleidtPromega Corporation, Madison, Wisconsin, United States of America.
Keith V WoodPromega Corporation, Madison, Wisconsin, United States of America.
Thomas A KirklandPromega Biosciences, Inc., San Luis Obispo, California, United States of America.ORCID 0000-0003-0859-5785
Promega (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Firefly luciferase-based ATP detection assays are frequently used as a sensitive, cost-efficient method for monitoring hygiene in many industrial settings. Solutions of detection reagent, containing a mixture of a substrate and luciferase enzyme that produces photons in the presence of ATP, are relatively unstable and maintain only a limited shelf life even under refrigerated conditions. It is therefore common for the individual performing a hygiene test to manually prepare fresh reagent at the time of monitoring. To simplify sample processing, a liquid detection reagent with improved thermal stability is needed. The engineered firefly luciferase, Ultra-Glo™, fulfills one aspect of this need and has been valuable for hygiene monitoring because of its high resistance to chemical and thermal inactivation. However, solutions containing both Ultra-Glo™ luciferase and its substrate luciferin gradually lose the ability to effectively detect ATP over time. We demonstrate here that dehydroluciferin, a prevalent oxidative breakdown product of luciferin, is a potent inhibitor of Ultra-Glo™ luciferase and that its formation in the detection reagent is responsible for the decreased ability to detect ATP. We subsequently found that dialkylation at the 5-position of luciferin (e.g., 5,5-dimethylluciferin) prevents degradation to dehydroluciferin and improves substrate thermostability in solution. However, since 5,5-dialkylluciferins are poorly utilized by Ultra-Glo™ luciferase as substrates, we used structural optimization of the luciferin dialkyl modification and protein engineering of Ultra-Glo™ to develop a luciferase/luciferin pair that shows improved total reagent stability in solution at ambient temperature. The results of our studies outline a novel luciferase/luciferin system that could serve as foundations for the next generation of bioluminescence ATP detection assays with desirable reagent stability.

Indexed as

Adenosine TriphosphateAlkylationFirefly LuciferinIndicators and ReagentsLuciferases, FireflyLuminescent AgentsLuminescent MeasurementsSubstrate SpecificityTemperatureAdenosine TriphosphateFirefly LuciferinIndicators and ReagentsLuciferases, FireflyLuminescent Agents

Identifiers

PMID33315907
PMCPMC7735563
OpenAlexW3113201731

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.